UTICA, N.Y., Oct. 25 /PRNewswire-FirstCall/ -- CONMED Corporation
(Nasdaq: CNMD) today announced financial results for the third quarter and
nine months ended September 30, 2005. Sales for the 2005 third quarter
increased 13.4% to $150.0 million compared to $132.3 million in the third
quarter of 2004. The Endoscopic Technologies product line acquired from C.R.
Bard in September 2004 contributed $15.2 million to the $150.0 million in
total sales for the quarter. Net income was $7.9 million in the quarter, or
$0.26 per diluted share, an increase from the $1.7 million recorded in the
third quarter last year, or $0.06 per diluted share.
Mr. Joseph J. Corasanti, President and Chief Operating Officer, noted, "We
are pleased to see that the Endoscopic Technologies product line, acquired
last year, continues to contribute to our top line and to gross margin
improvements. Also, our international sales growth has met our expectations
for the third quarter as well as for the nine months of 2005. However, our
domestic sales growth in the third quarter was less than we had anticipated
and less than the preceding seven quarters."
He added, "Typically we see a seasonally reduced amount of business in the
third quarter because patients and surgeons tend to postpone surgeries from
the summer vacation time to other times of the year. This year the trend was
even more pronounced. We believe that economic conditions in the United
States, hurricanes in the southeast region of the United States, and reduced
consumer confidence in general have caused a slowing in elective surgery
procedures. Further, hospitals and surgery centers seem to be taking longer to
reach buying decisions on capital equipment. We believe that the factors
behind the slowdown in elective surgeries and longer equipment buying cycles
will be short-lived and that we will return to normal domestic sales growth
rates in 2006."
On a pro forma basis, excluding transition charges related to an
acquisition and other unusual charges (see attached reconciliation for
additional information), non-GAAP net income for the 2005 third quarter was
$9.6 million, or $0.32 per diluted share, compared to $11.5 million or $0.38
per diluted share in the comparable third quarter of 2004.
For the nine months ended September 30, 2005, sales increased 16.8% to
$464.1 million with net income of $29.2 million and diluted earnings per share
of $0.98. This compares to the nine months ended September 30, 2004 with sales
of $397.2 million, net income of $26.0 million and diluted earnings per share
of $0.86. On a pro forma basis, excluding transition and other unusual
charges, 2005 nine-month non-GAAP net income and diluted earnings per share
were $36.5 million and $1.22, respectively. These compare to 2004 nine-month
non-GAAP net income and diluted earnings per share of $35.8 million and $1.18,
respectively.
As previously disclosed, while year-to-date sales are generally meeting
the Company's objectives, third quarter 2005 sales were below original
expectations of $153 - $156 million, primarily due to lower-than-anticipated
elective surgeries in the United States. Anecdotal information suggests that
elective surgeries in many regions of the United States may have been
particularly low in the summer of 2005. In the third quarter, sales of capital
equipment appear to have also slowed as hospital customers appear to be taking
longer to conclude the buying process.
Outside the United States, the Company's rate of sales growth compared
favorably to expectations, up 11%, year over year for the third quarter. This
excludes the effects of the Endoscopic Technologies acquisition which was
acquired on September 30, 2004. The effects of foreign exchange translation
changes in the third quarter of 2005 were a benefit to sales in the amount of
$0.9 million.
Following is a summary of the Company's sales by product line for the
three and nine-months ended September, 2005 (in millions):
Three Months Ended Nine Months Ended
September Growth September Growth
2004 2005 2004 2005
Arthroscopy $50.8 $ 50.2 -1.2% $150.1 $159.0 5.9%
Powered Surgical
Instruments 30.2 30.5 1.0% 95.1 99.9 5.0%
Electrosurgery 21.2 22.4 5.7% 62.0 65.9 6.3%
Endosurgery 11.4 12.9 13.2% 34.9 38.1 9.2%
Patient Care 18.7 18.8 0.5% 55.1 56.8 3.1%
132.3 134.8 1.9% 397.2 419.7 5.7%
Endoscopic
Technologies - 15.2 - 44.4
$132.3 $150.0 13.4% $397.2 $464.1 16.8%
CONMED's gross margin, excluding Endoscopic Technologies acquisition
transition charges associated with moving manufacturing from C.R. Bard
facilities to our own plants, has improved during 2005 to 52.7% and 51.9%,
respectively, for the nine months and three months ended September 30, 2005.
In 2004 the comparable gross margin percentages were 52.0% for the nine month
and 51.0% for the three month periods. The improving gross margin is a result
of the inclusion in the Company's sales base of the Endoscopic Technologies
product line, with gross margins that are higher than the Company's overall
average. The positive impact of the gross margin was partly offset by the
rising cost of petroleum-based plastic raw materials and transportation costs.
The Company's selling and administrative costs have increased during the
first nine months of 2005 as a result of the inclusion of the Endoscopic
Technologies product line acquisition. Additionally, administrative costs for
year-to-date and the third quarter 2005 were affected by increased litigation
expenses associated with antitrust litigation initiated against a competitor.
We expect these litigation expenses will increase in the fourth quarter of
2005 when we respond to the motion for summary judgment filed, as expected, on
October 21, 2005.
Outlook
The Company anticipates that slower-growing surgical procedure trends and
the longer closing process for capital equipment purchases experienced in the
third quarter of 2005 will continue throughout the remainder of the year.
Therefore, management projects limited fourth quarter domestic sales growth,
supplemented by solid international sales improvement of approximately 11%.
This growth mix, as well as higher petroleum-based plastic raw materials and
litigation costs, are expected to result in estimated sales of
$163 - $166 million and non-GAAP diluted earnings per share of $0.36 - $0.40.
GAAP diluted earnings per share in the fourth quarter of 2005 is estimated to
be $0.30 - $0.34.
In 2006, CONMED believes that a number of factors will have a positive
effect on the Company's sales growth rate, including the anticipated new
product pipeline, improved salesforce performance and return to normal
elective procedure rates. With these underlying factors, the Company expects
to achieve top-line organic growth of approximately 6% for 2006 over 2005, an
improvement from the expected 4% organic growth in 2005. It is the Company's
intention to provide net income and earnings per share guidance for 2006 when
the results for the fourth quarter of 2005 are announced.
CONMED Profile
CONMED is a medical technology company with an emphasis on surgical
devices and equipment for minimally invasive procedures and monitoring. The
Company's products serve the clinical areas of arthroscopy, powered surgical
instruments, electrosurgery, cardiac monitoring disposables, endosurgery and
endoscopic technologies. They are used by surgeons and physicians in a variety
of specialties including orthopedics, general surgery, gynecology,
neurosurgery, and gastroenterology. Headquartered in Utica, New York, the
Company's 3,100 employees distribute its products worldwide from eleven
manufacturing locations.
Forward-Looking Information
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking statements
in this press release involve risks and uncertainties which could cause actual
results, performance or trends, including the above mentioned anticipated
revenues and earnings, to differ materially from those expressed in the
forward-looking statements herein or in previous disclosures. The Company
believes that all forward-looking statements made by it have a reasonable
basis, but there can be no assurance that management's expectations, beliefs
or projections as expressed in the forward-looking statements will actually
occur or prove to be correct. In addition to general industry and economic
conditions, factors that could cause actual results to differ materially from
those discussed in the forward-looking statements in this press release
include, but are not limited to: (i) the failure of any one or more of the
assumptions stated above, to prove to be correct; (ii) the risks relating to
forward-looking statements discussed in the Company's Annual Report on Form
10-K for the fiscal year ended December 31, 2004; (iii) cyclical purchasing
patterns from customers, end-users and dealers; (iv) timely release of new
products, and acceptance of such new products by the market; (v) the
introduction of new products by competitors and other competitive responses;
(vi) the possibility that any acquisition (and its integration) or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; (vii) increasing costs for raw material, transportation, or
litigation; and/or (viii) the Company's ability to devise and execute
strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(in thousands except per share amounts)
(unaudited)
Three months ended Nine months ended
September 30, September 30,
2004 2005 2004 2005
Net sales $132,289 $149,970 $397,165 $464,105
Cost of sales 64,802 72,205 190,605 219,576
Cost of sales,
acquisition-transition
- Note A - 1,811 - 5,976
Gross profit 67,487 75,954 206,560 238,553
Selling and
administrative 42,719 52,649 128,921 158,740
Research and
development 4,706 6,409 14,281 18,633
Write-off of purchased
in-process research and
development assets -
Note B 13,700 - 13,700 -
Other expense - Note C 867 779 867 5,255
61,992 59,837 157,769 182,628
Income from operations 5,495 16,117 48,791 55,925
Interest expense 3,189 4,034 9,053 11,364
Income before
income taxes 2,306 12,083 39,738 44,561
Provision for
income taxes 607 4,169 13,708 15,374
Net income $ 1,699 $ 7,914 $ 26,030 $ 29,187
Per share data:
Net Income
Basic $ .06 $ .27 $ .88 $ .99
Diluted .06 .26 .86 .98
Weighted average
common shares
Basic 29,816 29,470 29,618 29,358
Diluted 30,347 29,951 30,241 29,853
Note A - Included in cost of sales in the three and nine months ended
September 30, 2005 are approximately $1.8 million and $6.0 million,
respectively, in acquisition-transition costs.
Note B . During the three and nine months ended September 30, 2004, we
wrote-off the preliminary estimate of purchased in-process research and
development assets related to the Bard Endoscopic Technologies
acquisition.
Note C - Included in other expense in the three and nine months ended
September 30, 2004 are $0.9 million in acquisition-related costs.
Included in other expense in the three months ended September 30, 2005
are the following: $0.1 million in costs related to the termination of a
product offering and $0.7 million in acquisition-related costs. Included
in other expense in the nine months ended September 30, 2005 are the
following: $0.7 million in environmental settlement costs, $1.1 million
in costs related to the termination of a product offering and
$3.5 million in acquisition-related costs.
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS
December 31, September 30,
2004 2005
Current assets:
Cash and cash equivalents $ 4,189 $ 1,918
Accounts receivable, net 74,593 81,758
Inventories 127,935 152,297
Deferred income taxes 13,733 13,090
Other current assets 2,492 3,116
Total current assets 222,942 252,179
Property, plant and equipment, net 101,465 103,443
Goodwill and other intangible
assets, net 529,717 528,306
Other assets 18,701 17,982
Total assets $872,825 $901,910
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $ 4,037 $ 4,121
Other current liabilities 59,024 58,738
Total current liabilities 63,061 62,859
Long-term debt 290,485 266,950
Deferred income taxes 51,433 63,242
Other long-term liabilities 19,863 25,901
Total liabilities 424,842 418,952
Shareholders' equity:
Capital accounts 226,444 234,955
Retained earnings 227,938 257,125
Accumulated other comprehensive loss (6,399) (9,122)
Total equity 447,983 482,958
Total liabilities and
shareholders' equity $872,825 $901,910
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
(in thousands)
(unaudited)
Nine months ended
September 30,
2004 2005
Cash flows from operating activities:
Net income $26,030 $ 29,187
Adjustments to reconcile net income
to net cash provided by operating activities:
Depreciation and amortization 19,829 22,924
Deferred income taxes 8,984 11,010
Sale of accounts receivable (3,000) (6,000)
Write-off of purchased in-process
research and development asset 13,700 -
Other, net (11,908) (18,329)
Net cash provided by operating activities 53,635 38,792
Cash flow from investing activities:
Payments related to business acquisitions,
net of cash acquired (80,000) (364)
Purchases of property, plant,
and equipment (7,529) (12,233)
Net cash used in investing activities (87,529) (12,597)
Cash flow from financing activities:
Payments on debt (24,608) (29,451)
Proceeds of debt 50,000 6,000
Proceeds from common stock issued
under employee plans 9,818 16,576
Repurchase of common stock - (12,750)
Other, net 3,694 (5,595)
Net cash provided by financing activities 38,904 (25,220)
Effect of exchange rate change
on cash and cash equivalents (773) (3,246)
Net increase in cash and cash equivalents 4,237 (2,271)
Cash and cash equivalents at beginning of period 5,986 4,189
Cash and cash equivalents at end of period $10,223 $ 1,918
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE UNUSUAL ITEMS
(In thousands except per share amounts)
(unaudited)
Three months ended
September 30,
2004 2005
Reported net income $ 1,699 $ 7,914
Acquisition-transition costs included
in cost of sales - 1,811
Write-off of purchased in-process research
and development assets 13,700 -
Termination of product offering - 120
Other acquisition-related costs 867 659
Total other expense 867 779
Acquisition-related interest expense 360 -
Unusual expense before income taxes 14,927 2,590
Provision (benefit) for income taxes on
unusual expense (5,150) (894)
Net income before unusual items $ 11,476 $ 9,610
Per share data:
Reported net income
Basic $ 0.06 $ 0.27
Diluted 0.06 0.26
Net income before unusual items
Basic $ 0.38 $ 0.33
Diluted 0.38 0.32
Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE UNUSUAL ITEMS
(In thousands except per share amounts)
(unaudited)
Nine months ended
September 30,
2004 2005
Reported net income $ 26,030 $ 29,187
Acquisition-transition costs included
in cost of sales - 5,976
Write-off of purchased in-process research
and development assets 13,700 -
Environmental settlement costs - 698
Termination of product offering - 1,069
Other acquisition-related costs 867 3,488
Total other expense 867 5,255
Acquisition-related interest expense 360 -
Unusual expense before income taxes 14,927 11,231
Provision (benefit) for income taxes
on unusual expense (5,150) (3,875)
Net income before unusual items $ 35,807 $ 36,543
Per share data:
Reported net income
Basic $ 0.88 $ 0.99
Diluted 0.86 0.98
Net income before unusual items
Basic $ 1.21 $ 1.24
Diluted 1.18 1.22
Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
SOURCE CONMED Corporation
 back to top
Related links:
http://www.conmed.com
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; or Investors and Media:
Julie Huang, or Theresa Kelleher, both of Financial Dynamics,
+1-212-850-5600
|
